PMID: 2506596Jan 1, 1989Paper

Differences in the time course of dopaminergic supersensitivity following chronic administration of haloperidol, molindone, or sulpiride

Psychopharmacology
E S ProsserJ G Csernansky

Abstract

The onset and persistence of changes in 3H-spiroperidol binding to dopamine (DA) D2 receptors were examined in rat mesolimbic and striatal brain regions following daily administration of haloperidol, molindone, or sulpiride for 3, 7, 14, or 28 days. Neuroleptic dose equivalencies were determined by inhibition of 3H-spiroperidol in vivo binding in several rat brain regions. Changes in locomotor and stereotyped responses to the specific DA D2 agonist quinpirole were examined 3 days after the last treatment dose. Haloperidol or molindone administration increased mean stereotypy scores and striatal DA D2 receptor densities throughout the 28-day treatment period. In contrast, mesolimbic DA D2 receptor densities were transiently increased and returned to control values, after 28 days of haloperidol or molindone treatment. Sulpiride treatment increased mean stereotypy scores and striatal Bmax values, but had no effect on locomotion or mesolimbic dopamine receptor density. Additionally, the magnitude of change in the various measures of brain DA function varied among the three neuroleptic treatment groups. Results from this study suggest that mesolimbic and striatal brain regions differ in their response to long-term neuroleptic admini...Continue Reading

References

Dec 15, 1978·Psychopharmacology·P Muller, P Seeman
Jan 11, 1979·Nature·J W Kebabian, D B Calne
Jun 11, 1979·Life Sciences·C J Niemegeers, P A Janssen
Dec 1, 1985·Pharmacology, Biochemistry, and Behavior·W R Klemm
Jan 14, 1986·European Journal of Pharmacology·P H AndersenC Braestrup
Jan 1, 1973·The American Journal of Psychiatry·H L Klawans
Jan 1, 1980·The American Journal of Psychiatry·G Chouinard, B D Jones
Apr 23, 1982·European Journal of Pharmacology·K S KendlerK L Davis
Dec 3, 1984·Life Sciences·J C Stoof, J W Kebabian
Jan 1, 1981·Psychopharmacology·R S KamerL J Kaplan
Jan 1, 1982·General Pharmacology·S E O'Connor, R A Brown
Jan 1, 1980·International Pharmacopsychiatry·J BannetR H Belmaker

❮ Previous
Next ❯

Citations

May 1, 1993·Pharmacology, Biochemistry, and Behavior·T BaptistaL Hernández
Mar 1, 1997·Behavioural Brain Research·M E BardgettJ G Csernansky
Nov 15, 2006·Nihon yakurigaku zasshi. Folia pharmacologica Japonica·Tsuyoshi HiroseTetsuro Kikuchi
Jul 23, 1999·Annals of the New York Academy of Sciences·J N Joyce, E V Gurevich
Mar 21, 2007·Progress in Neuro-psychopharmacology & Biological Psychiatry·Daniela Fukue FukushiroRoberto Frussa-Filho
Jan 30, 2014·Clinical and Experimental Pharmacology & Physiology·André W HollaisRoberto Frussa-Filho
Oct 22, 2013·Progress in Neuro-psychopharmacology & Biological Psychiatry·Jing QiaoMing Li
Jan 27, 2007·The Cochrane Database of Systematic Reviews·A BagnallR Lewis

❮ Previous
Next ❯

Related Concepts

Related Feeds

Amygdala: Sensory Processes

Amygdalae, nuclei clusters located in the temporal lobe of the brain, play a role in memory, emotional responses, and decision-making. Here is the latest research on sensory processes in the amygdala.

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here